Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Adia Nutrition Inc. (OTC Pink: ADIA) has filed for uplisting to the OTCQB Venture Market following a successful independent audit with Astra Audit and Advisory LLC on April 1, 2025. The company is leveraging OTC Markets to handle its Form 15c2-11 filing, which will enable broker-dealers to quote ADIA securities and enhance market maker participation.
The company has also requested the Non-Objecting Beneficial Owners (NOBO) list to improve direct communication with shareholders. These strategic moves aim to increase transparency, liquidity, and market visibility as Adia continues its focus on regenerative medicine, including Umbilical Cord Stem Cell therapies and Autologous Hematopoietic Stem Cell Transplantation. The company's long-term goal includes a potential Nasdaq Small Cap listing.
Adia Nutrition Inc. (OTC Pink: ADIA) ha presentato la richiesta di passaggio al OTCQB Venture Market dopo un audit indipendente di successo effettuato da Astra Audit and Advisory LLC il 1° aprile 2025. L'azienda utilizza OTC Markets per gestire la presentazione del modulo 15c2-11, che permetterà ai broker-dealer di quotare i titoli ADIA e aumentare la partecipazione dei market maker.
Inoltre, la società ha richiesto la lista dei Proprietari Benefici Non Obiettivi (NOBO) per migliorare la comunicazione diretta con gli azionisti. Queste mosse strategiche mirano ad aumentare trasparenza, liquidità e visibilità sul mercato, mentre Adia continua a concentrarsi sulla medicina rigenerativa, comprese le terapie con cellule staminali del cordone ombelicale e il trapianto autologo di cellule staminali ematopoietiche. L'obiettivo a lungo termine dell’azienda include una possibile quotazione sul Nasdaq Small Cap.
Adia Nutrition Inc. (OTC Pink: ADIA) ha solicitado su inclusión en el OTCQB Venture Market tras una auditoría independiente exitosa realizada por Astra Audit and Advisory LLC el 1 de abril de 2025. La empresa está utilizando OTC Markets para gestionar la presentación del Formulario 15c2-11, lo que permitirá a los corredores-dealers cotizar los valores de ADIA y aumentar la participación de los creadores de mercado.
Además, la compañía ha solicitado la lista de Propietarios Beneficiarios No Opositores (NOBO) para mejorar la comunicación directa con los accionistas. Estas acciones estratégicas buscan aumentar la transparencia, la liquidez y la visibilidad en el mercado, mientras Adia continúa enfocándose en la medicina regenerativa, incluyendo terapias con células madre del cordón umbilical y trasplante autólogo de células madre hematopoyéticas. El objetivo a largo plazo de la empresa incluye una posible cotización en Nasdaq Small Cap.
Adia Nutrition Inc. (OTC Pink: ADIA)는 2025년 4월 1일 Astra Audit and Advisory LLC의 독립 감사 성공에 따라 OTCQB 벤처 마켓으로 상장 이전 신청을 했습니다. 회사는 OTC Markets를 통해 Form 15c2-11 제출을 처리하여 중개상들이 ADIA 증권을 호가할 수 있도록 하고, 마켓 메이커 참여를 확대할 예정입니다.
또한, 회사는 비이의 수익자 명단(NOBO)을 요청하여 주주와의 직접 소통을 개선하고자 합니다. 이러한 전략적 조치는 투명성, 유동성 및 시장 가시성을 높이는 것을 목표로 하며, Adia는 제대혈 줄기세포 치료 및 자가 조혈모세포 이식 등 재생 의학에 계속 집중하고 있습니다. 회사의 장기 목표에는 나스닥 스몰캡 상장 가능성도 포함됩니다.
Adia Nutrition Inc. (OTC Pink : ADIA) a déposé une demande de passage au OTCQB Venture Market suite à un audit indépendant réussi réalisé par Astra Audit and Advisory LLC le 1er avril 2025. La société utilise OTC Markets pour gérer le dépôt du formulaire 15c2-11, ce qui permettra aux courtiers-négociants de coter les titres ADIA et d’accroître la participation des teneurs de marché.
La société a également demandé la liste des bénéficiaires effectifs non opposants (NOBO) afin d’améliorer la communication directe avec les actionnaires. Ces initiatives stratégiques visent à augmenter la transparence, la liquidité et la visibilité sur le marché, tandis qu’Adia poursuit son développement dans la médecine régénérative, notamment les thérapies à base de cellules souches du cordon ombilical et la transplantation autologue de cellules souches hématopoïétiques. L’objectif à long terme de l’entreprise inclut une éventuelle cotation au Nasdaq Small Cap.
Adia Nutrition Inc. (OTC Pink: ADIA) hat nach einer erfolgreichen unabhängigen Prüfung durch Astra Audit and Advisory LLC am 1. April 2025 den Antrag auf Aufnahme in den OTCQB Venture Market gestellt. Das Unternehmen nutzt OTC Markets, um die Einreichung des Formulars 15c2-11 zu verwalten, was es Broker-Dealern ermöglicht, ADIA-Wertpapiere zu quotieren und die Teilnahme von Market Makern zu erhöhen.
Das Unternehmen hat außerdem die Liste der Nicht-Einspruch erhebenden wirtschaftlichen Eigentümer (NOBO) angefordert, um die direkte Kommunikation mit den Aktionären zu verbessern. Diese strategischen Maßnahmen zielen darauf ab, Transparenz, Liquidität und Marktsichtbarkeit zu erhöhen, während Adia weiterhin seinen Fokus auf regenerative Medizin legt, einschließlich Therapien mit Nabelschnur-Stammzellen und autologer hämatopoetischer Stammzelltransplantation. Das langfristige Ziel des Unternehmens umfasst eine mögliche Notierung im Nasdaq Small Cap.
- Filing for OTCQB uplisting indicates progress in corporate development and potential for increased market visibility
- Successful completion of independent audit demonstrates financial transparency
- OTC Markets handling of Form 15c2-11 should improve trading efficiency and liquidity
- Strategic move to obtain NOBO list enables direct shareholder communication
- Currently trading on OTC Pink, the lowest tier of OTC Markets
- Uplisting process is still pending and subject to approval
- No guarantee of successful transition to OTCQB or future Nasdaq listing
Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products.
As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery—key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach.
OTCQB Up Listing
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/252323_adia1en.jpg
Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work—such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)—while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities.
"We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence."
With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine.
For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252323
FAQ
What is the significance of ADIA's OTCQB uplisting filing?
How will Form 15c2-11 handling by OTC Markets benefit ADIA stock?
What is the purpose of Adia Nutrition requesting the NOBO list?
What are Adia Nutrition's future plans beyond OTCQB uplisting?
